TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04431752

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging Scan
Description: The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging Scan
Description: The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging Scan
Description: The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging Scan
Description: The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.

Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging Scan
Description: The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
Study: NCT05580198

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial sonography.
Description: Transcranial sonography examination to determine the brainstem raphe echogenicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial sonography.
Description: Transcranial sonography examination to determine the brainstem raphe echogenicity.
Study: NCT04988399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
Study: NCT04886388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BT-001
Description: BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician-guided Standard of Care for type 2 diabetes
Description: Current ADA Standard of Care Guidelines for type 2 diabetes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician-guided Standard of Care for type 2 diabetes
Description: Current ADA Standard of Care Guidelines for type 2 diabetes
Study: NCT05555862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: artesunate formulated as intra-anal suppositories
Study: NCT06189209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: Tenalisib will be administered 800mg BID, orally
Study: NCT05046925

Intervention type: PROCEDURE
Intervention: postoperatively transferral to PACU
Description: patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.

Intervention type: PROCEDURE
Intervention: postoperatively transferral to ICU
Description: patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
Study: NCT06124105

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arterial blood gases
Description: measurement of partial oxygen pressure in urine by arterial blood gas device
Study: NCT06279494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT
Study: NCT05555862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo intra-anal suppository
Study: NCT06469307

Intervention type: OTHER
Intervention: DIVERSE Review Process
Description: A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.

Intervention type: OTHER
Intervention: DIVERSE Review Process
Description: A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
Study: NCT04908124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant A
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant A
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant B
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant B
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant C
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant C
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant D
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant D
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant E
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant E
Description: Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
Study: NCT06218134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human Wharton's jelly-derived mesenchymal stem cells
Description: human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
Study: NCT04641195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc (zinc gluconate)
Description: 40mg of zinc gluconate taken once per day from enrollment to 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)
Description: 180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
Study: NCT06279494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: 0.5g bid orally, from -3d to +60d post haplo-HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 2.5 mg/kg, from -5d to -2d
Study: NCT05727150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap
Description: Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
Study: NCT06526325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced golgi tendon organ stimulation
Description: Enhanced Golgi Tendon Organ Stimulation is a method that can be used by physiotherapists and doctors. The Golgi tendon organ is the proprioceptors located in the tendon adjacent to the myotendinous junction. It is applied using two separate heads, the stimulator and the algometer. The sternocleidomastoideus, platysma, colli longus, capitis longus, scalene, rhomboid major and minor, levator scapulae and trapezius muscles and their tendons will be vibrated with a stimulator for 30 seconds, then 0.5 kilograms of pressure will be applied with an algometer from the origin to the insertion of the muscle in the region at 0.5 centimetre intervals at an angle of 90 degrees.
Study: NCT06392893

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meat product without additives and allergens
Description: Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of meat products without additives and allergens (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Commercial meat product
Description: Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of commercial meat products (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.
Study: NCT05140083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA Evans Blue
Description: Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
Study: NCT05033483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Fumarate
Description: Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Gelatin capsule containing microcrystalline cellulose
Study: NCT06239545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study: NCT05393297

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging: Intra-treatment FDG-PET-CT and MRI
Description: FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation
Description: Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
Study: NCT03816007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga and Mantram Repetition
Description: An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Veteran Calm
Description: A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
Study: NCT05437016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HUBER exercises
Description: All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercises
Description: All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
Study: NCT05264701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist supervised exercise training
Description: Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training via phone app
Description: Exercise training for 12 weeks will be given over the developed phone application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Description: The program will be consist of 12 weeks of physical activity recommendations.
Study: NCT05223972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Treatment
Description: Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Treatment
Description: Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise
Study: NCT06019065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJA001
Description: AJA001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06155110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardiomyopeptidin
Description: cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
Study: NCT05489562

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoral Suction
Description: stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
Study: NCT06300983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducative
Description: The intervention consiste of 5 sessions (Table 1), with each lasting 100 minutes and delivered on a weekly basis. Individual meetings will be conducted with each participant prior to starting the group work. These were considered pre-intervention sessions, during which patients provided informed consent to participate in the study and the first assessment tests were administered.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group, which do not receive any psychoeducative intervention
Study: NCT06149845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Pulpotomy
Description: Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
Study: NCT05715424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six interventions for children and adolescents
Description: * Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six interventions for children and adolescents
Description: * Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six interventions for children and adolescents
Description: * Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action.
Study: NCT06333977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC542019
Description: oral dose, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo